Business Context and Reporting Period
Company: Pheton Holdings Ltd (Ticker: PTHL)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Pheton is a Cayman Islands holding company conducting operations primarily through its PRC subsidiary, Beijing Feitian. The company develops and commercializes Treatment Planning Systems (TPS) for brachytherapy (radioactive particle implantation) and sells related medical auxiliary supplies. Its lead product is the Feitian Treatment Planning Software (FTTPS).
Recent Capital Event: The company completed its Initial Public Offering (IPO) on September 6, 2024, selling 2,250,000 Class A Ordinary Shares at $4.00 per share, generating gross proceeds of approximately $9.0 million.
Key Financial Metrics
| Metric | 2024 (USD) | 2023 (USD) | 2022 (USD) |
|---|---|---|---|
| Revenue | $448,196 | $628,591 | $679,777 |
| Gross Profit | $381,155 | $470,828 | $558,150 |
| Gross Margin | 85.04% | 74.90% | 82.11% |
| Net Income (Loss) | $(660,588) | $(241,217) | $83,980 |
| Operating Expenses | $1,151,421 | $777,508 | $530,629 |
| Cash and Restricted Cash | $6,159,823 | $227,450 | $72,288 |
| Working Capital | $6,139,109 | $(672,903) | N/A |
| Debt (Short-term Bank Loans) | $247,969 | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 28.70% to $448,196 in 2024 compared to 2023. This was driven by a 39.35% drop in FTTPS sales revenue (due to a 25% decrease in sales volume and a 19.14% decrease in average contract prices) partially offset by a 308.70% increase in Medical Auxiliary Supplies sales.
- Widening Net Loss: Net loss increased significantly by 173.86% to $660,588 in 2024. This was primarily due to a 48.09% increase in operating expenses, specifically a 76.65% rise in General and Administrative (G&A) expenses related to audit, legal, and accounting fees associated with becoming a public company.
- Liquidity Improvement: Cash and restricted cash increased dramatically from $227,450 in 2023 to $6,159,823 in 2024, primarily due to net proceeds of approximately $7.8 million from the September 2024 IPO.
- Debt Incurrence: The company incurred short-term bank loans totaling $247,969 in 2024, secured by guarantees from the CEO and a Director, whereas no such debt existed in 2023.
Guidance, Outlook, and Risks
- Internal Control Weaknesses: Management and the independent auditor identified three material weaknesses in internal control over financial reporting as of December 31, 2024. These include insufficient in-house personnel with U.S. GAAP knowledge, lack of formal risk assessment policies, and deficiencies in IT general controls (including cybersecurity and access management).
- Outlook: Management believes current cash and working capital are sufficient to support operations for the next 12 months. The company plans to use remaining IPO proceeds for R&D, market expansion (specifically targeting Southeast Asia), and internal control improvements.
- Key Risks:
- Regulatory Environment: Significant risks related to PRC laws, including cybersecurity reviews, data security regulations, and potential restrictions on overseas listings.
- Concentration Risk: Revenue is concentrated in China. In 2024, the top two customers accounted for 28% of total revenue. The top three suppliers accounted for 59% of total purchases.
- Product Dependence: The company relies heavily on the commercialization of FTTPS. Failure to gain market acceptance or adapt to technological changes could materially harm operations.
- PCAOB Inspection: While the PCAOB has recently completed inspections of firms in China, ongoing geopolitical tensions could impact the ability to inspect auditors, potentially leading to trading prohibitions under the HFCA Act.
Investor Verification Checklist
- Remediation of Internal Controls: Verify the specific steps and timeline management has established to remediate the three identified material weaknesses in internal controls.
- Revenue Sustainability: Assess the reasons for the 25% drop in FTTPS sales volume and the 19% drop in average contract price to determine if this trend is structural or cyclical.
- Use of IPO Proceeds: Monitor the deployment of the ~$6.05 million in remaining IPO proceeds to ensure alignment with stated growth strategies (R&D and international expansion).
- Regulatory Compliance: Confirm the status of the company's compliance with PRC cybersecurity and data security regulations, particularly regarding the "Cybersecurity Review Measures."
- Related Party Transactions: Review the nature of the $50,000 advance to the CEO and the $247,969 in bank loans guaranteed by the CEO and a Director.